NASDAQ : ALMR
Alamar Biosciences, Inc. — Key statistics
Healthcare · Medical Instruments & Supplies · United States
Last price 30.6 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.12B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.02B |
| Enterprise Value | 1.83B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 69.39M |
| Shares Outstanding | 69.39M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +378.52% |
| Owned by Insiders (%) | 10.44% |
| Owned by Institutions (%) | 35.39% |
| Float | 41.60M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 20.21 |
| Forward PS | 14.60 |
| PB Ratio | 6.79 |
| P/TBV Ratio | 6.52 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 18.23 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 11.85 |
| Quick Ratio | 9.67 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -54.03 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -11.22% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $351,119 |
| Profits Per Employee | -$173,640 |
| Employee Count | 286 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 1.04M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 30.55 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 47.71 |
| Average Volume (20 Days) | 822,557 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.68M |
| Short Previous Month | 2.81M |
| Short % of Shares Out | 3.86% |
| Short % of Float | 6.43% |
| Short Ratio (days to cover) | 3.53 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 100.42M |
| Gross Profit | 58.91M |
| Operating Income | -40.74M |
| Pretax Income | -48.63M |
| Net Income | -49.66M |
| EBITDA | -37.48M |
| EBIT | -40.74M |
| Loss Per Share | -$2.10 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 250.05M |
| Total Debt | 51.41M |
| Net Cash | 198.65M |
| Net Cash Per Share | $2.86 |
| Equity (Book Value) | 312.86M |
| Book Value Per Share | 4.51 |
| Working Capital | 303.42M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -60.33M |
| Capital Expenditures | -8.31M |
| Depreciation & Amortization | 3.26M |
| Net Borrowing | 60.35M |
| Free Cash Flow | -68.64M |
| FCF Per Share | -$0.99 |
Margins
| Measure | Value |
|---|
| Gross Margin | 58.66% |
| Operating Margin | -40.57% |
| Pretax Margin | -48.42% |
| Profit Margin | -49.45% |
| EBITDA Margin | -37.33% |
| EBIT Margin | -40.57% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -7.20% |
| FCF Yield | -3.38% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $35.40 |
| Price Target Difference | 21.36% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 44.56% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 12.1 |
| Piotroski F-Score | n/a |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |